Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Vanucizumab (DHA42302)

Host species:Humanized
Isotype:VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHA42302

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa

Clonality

Monoclonal

Target

Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A, ANG-2, ANGPT2, Angiopoietin-2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P15692 & O15123

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific, RG-7221, RG7221, RO5520985, CAS: 1448221-05-3

Clone ID

Vanucizumab

Data Image
  • Bioactivity
    Detects Human VEGFA in indirect ELISAs.
  • Bioactivity
    Detects Human ANGPT2 in indirect ELISAs.
  • SDS-PAGE
    SDS PAGE for Vanucizumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies, PMID: 33338877

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC), PMID: 32162804

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors, PMID: 29217526

The use of CrossMAb technology for the generation of bi- and multispecific antibodies, PMID: 27285945

Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling, PMID: 27529514

Novel anti-angiogenic therapeutic strategies in colorectal cancer, PMID: 26938715

Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment, PMID: 32865652

Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs, PMID: 27863175

Angiopoietin inhibitors: A review on targeting tumor angiogenesis, PMID: 33741382

Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model, PMID: 31394786

Datasheet

Document Download

Research Grade Vanucizumab.pdf

 

$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Vanucizumab [DHA42302]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only